Mektovi (binimetinib) is an oral kinase inhibitor that may be used in combination with encorafenib for the treatment of adults with:

unresectable or metastatic melanoma with a confirmed BRAF V600E or V600K mutation
metastatic non-small cell lung cancer (NSCLC) with a confirmed BRAF V600E mutation.
Mektovi is a reversible inhibitor of two proteins, mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2. These are upstream regulators of the extracellular signal-related kinase (ERK) pathway and blocking them results in an inhibition of extracellular signal-related kinase (ERK) phosphorylation as well as the viability and MEK-dependent phosphorylation of BRAF-mutations

For more information

Email :  sales@lexionpham

Website :  www.lexionpham.com

Medication :  https://lexionpham.com/index.php/product/buy-mektovi-for-sale-in-usa/